Thymus-derived lymphocyte enumeration in patients with uveal malignant melanoma

NORMAN T. FELBERG† and JERRY A. SHIELDS

From the 1Department of Molecular Biology of the Research Division and the 2Oncology Service, Wills Eye Hospital, and the 1,2Department of Ophthalmology and the 1Department of Biochemistry (NTR) of the Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA

SUMMARY Thymus-derived lymphocytes (T lymphocytes) were enumerated in patients with uveal malignant melanoma. Two T-lymphocyte subpopulations were determined, the active rosette forming cells (A-RFC) and the total rosette forming cells (T-RFC). Subjects were divided into the following groups: (a) pretreatment patients, (b) patients treated by enucleation, (c) patients treated by photocoagulation, (d) patients treated by cobalt plaque radiotherapy, (e) patients treated by enucleation who developed clinically detectable metastasis, and (f) normal controls. There were no differences in the numbers of A-RFC or T-RFC in the control population, pretreatment patients, and those treated in the different ways. Statistically significant depressions of A-RFC and T-RFC levels were seen in patients with metastatic lesions, suggesting that they had an impairment of immunocompetence, as measured by T-lymphocyte rosette formation.

Immune surveillance of solid tumours is generally accepted to be a function of the cell-mediated immune system. The ability of malignant cells to escape surveillance has been postulated to be due to a number of mechanisms such as the 'shedding' of tumour antigens or of other tumour products which can cause the suppression of the host's immune system. Cell-mediated immune responses have been demonstrated by in-vitro and in-vivo methods in patients with uveal malignant melanoma. In this study active rosette forming cells (A-RFC) and total rosette forming cells (T-RFC) were enumerated as a measure of cell-mediated immunity because they are reported to correlate well with cell-mediated immunity. A-RFC represent a special subset of T lymphocytes that have a higher affinity for sheep erythrocytes (E) and have a more consistent relationship to active immunity than do T-RFC. A-RFC probably represent 'activated' T lymphocytes, which are involved in ongoing immune responses.

Patients and methods

Patients. Eighty patients with the clinical diagnosis of uveal malignant melanoma who had not been treated were examined at the Oncology Service of the Wills Eye Hospital by one of the authors (J.A.S.) between 1977 and 1979. Therapy was provided according to established procedures. T lymphocytes were enumerated on these 80 patients. A post-therapy group consisted of the 80 pretreatment patients and an additional 24 patients who had their A-RFC and T-RFC evaluated after therapy. The patients in the post-therapy group included 62 patients who had been treated by enucleation, 15 patients treated by photocoagulation, and 27 patients treated by cobalt-60 plaque radiotherapy. During follow-up nine of the patients treated by enucleation developed metastasis confirmed either by biopsy, liver and bone scans, or necropsy. Patients receiving immunotherapy or chemotherapy were not included in this study. Normal controls consisted of 100 employees and volunteers without apparent disease or immunological depression.

Lymphocyte preparation. Ethylenediamine tetra-acetic acid (EDTA) anticoagulated blood was
Thymus-derived lymphocyte enumeration in patients with uveal malignant melanoma

separated on a Ficoll-hypaque discontinuous gradient. The lymphocyte layer was washed to remove thrombocytes. Viability by trypan blue exclusion was usually greater than 95%. Purity determined after Wright’s staining indicated that more than 95% of the cells were mononuclear leucocytes.

**Rosette formation.** Lymphocytes (0·1 ml of 5×10⁶ cells/ml of Hanks’s balanced salt solution, HBSS) was mixed in a 12×75 mm snap-cap plastic tube with an equal volume of sheep E (0·05%) and 20 µl of absorbed normal human serum. After 5 minutes at 37°C the tube was centrifuged at 100 g for 5 minutes. A-RFC were determined immediately and T-RFC were determined after an additional 90-minute incubation at 4°C according to Wybran et al.⁸

**Statistical comparisons.** Results were compared by Student’s t test. Probabilities less than 0·05 were considered significant.

**Results**

The numbers of A-RFC and T-RFC enumerated for the pretherapy patients and the controls are presented in Table 1. Overall no statistical difference was found between the two groups. During the course of the study no significant changes in the number of rosette forming cells were found in the patients treated by enucleation, photocoagulation, or cobalt plaque irradiation (Table 2). On the other hand those nine patients who developed metastatic melanoma had significantly (p<0·001) decreased levels of A-RFC and T-RFC. Serial enumerations of the two rosette forming cell populations in Fig. 1 showed decreasing levels of A-RFC and T-RFC even before the clinical detection of metastatic disease.

**Discussion**

The loss of immunocompetence as measured by rosette forming cells in the general circulation has been previously described in other malignancies at the time of diagnosis.⁹¹⁰ In this study we found no statistically significant differences in A-RFC and T-RFC levels at the time of diagnosis in 80 patients with malignant melanoma of the uvea (Table 1).

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Rosette forming cells in patients with uveal malignant melanoma after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Number</td>
</tr>
<tr>
<td></td>
<td>Active</td>
</tr>
<tr>
<td>Enucleation</td>
<td>62</td>
</tr>
<tr>
<td>Photocoagulation</td>
<td>15</td>
</tr>
<tr>
<td>Cobalt plaque</td>
<td>27</td>
</tr>
</tbody>
</table>

Values indicate the average and one standard deviation of the most recent follow-up data for each patient.

Recently several authors have suggested that an increased mortality rate following enucleation may be due to several possible mechanisms, including tumour dispersion during surgery, enucleation selectively given to those patients with large or rapidly growing tumours, or immunosuppression following surgery and anaesthetic.¹¹¹ To assess the immunocompetence of patients after therapy for their uveal malignant melanoma we compared the numbers of A-RFC and T-RFC in patients treated in different ways. We could find no differences in the numbers of A-RFC or T-RFC in the patients treated by enucleation photocoagulation or cobalt plaque irradiation (Table 2). Our results suggest that, if indeed these forms of therapy can induce an immunosuppression, it does not appear to be detectable with assays such as A-RFC or T-RFC enumeration.

Metastasis in other cancers has been associated with immunosuppression related to depressed numbers of rosette forming cells.¹⁵ Our study extends these observations to uveal malignant melanoma. We have detected depressed numbers of A-RFC and T-RFC as much as three months prior to the clinical detection of or death due to metastasis (Table 3, Fig. 1). In addition decreased T cells have been reported in patients with systemic metastases from uveal melanoma by a different rosetting technique.¹⁶ From the results of our study we do not believe that there is any diagnostic value in enumerating A-RFC and T-RFC lymphocytes in the initial evaluation of patients with uveal malignant melanoma. A-RFC and

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Rosette forming cells in patients with metastasis from uveal malignant melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis</td>
<td>Number</td>
</tr>
<tr>
<td></td>
<td>Active</td>
</tr>
<tr>
<td>Melanoma</td>
<td>9*</td>
</tr>
<tr>
<td>Control</td>
<td>100</td>
</tr>
</tbody>
</table>

*Rosette forming cells were assayed 3-11±4 months prior to the clinical detection of metastasis or death.

¹p<0·001 compared with controls or pretherapy patients.
Gamma-glutamyl transpeptidase, sensitive than the symbols. The while this of the authors are considered mean for the clinical value, since T-RFC enumeration may be more sensitive than A-RFC and T-RFC enumeration as a measure of immunocompetence, while other laboratory adjuncts that do not depend on host immunocompetence, such as serum gamma-glutamyl transpeptidase, may be more sensitive than rosette formation in detecting metastasis.

The authors thank James Augsburger, MD, for his helpful discussion of this study.

This work was supported in part by the Pennsylvania Lions Sight Conservation and Eye Research Foundation, Inc., NIH grant EY 04125 (Dr Felberg), and NIH grant EY 04041 and the Ocular Oncology Fund, Wills Eye Hospital (Dr Shields).

References